Compare IFBD & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFBD | ALZN |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.5M |
| IPO Year | 2020 | 2021 |
| Metric | IFBD | ALZN |
|---|---|---|
| Price | $1.29 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 425.9K | 107.2K |
| Earning Date | 05-01-2023 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.84 |
| 52 Week High | $2.18 | $2.68 |
| Indicator | IFBD | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 62.16 |
| Support Level | $0.87 | $1.69 |
| Resistance Level | $2.18 | $2.22 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 35.21 | 70.45 |
Infobird Co Ltd is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. The Company provides standard and customized customer relationship management cloud-based services, including SaaS and business process outsourcing (BPO) services. It generates revenue from the development and sale of software licenses for customized software, as well as from business integration solution services and digital advertising and marketing campaign services. Digital advertising revenue is generated from developing and executing advertising plans based on customer needs, and the Company generally provides limited warranties for work performed under its business integration solution contracts. The Company generates maximum revenue from its operations in Mainland China.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.